Halozyme Therapeutics, Inc.
HALO
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other tā¦ read more
Healthcare
Biotechnology
20 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$67.27
Price+2.64%
$1.73
1Y
Price
Market Cap
$7.868b
Mid
Price/Earnings 3y Avg5y Avg
15.4x
Premium
Premium
Financials Overview
Key metrics over the past few years+59.1%
EBITDA Margin+39.2%
Net Profit Margin+64.3%
Free Cash Flow MarginRevenue
$1.179b
+4.1%
1y CAGR+26.2%
3y CAGR+36.1%
5y CAGREarnings
$557.278m
+13.2%
1y CAGR+0.9%
3y CAGR+53.7%
5y CAGREPS
$4.37
+15.2%
1y CAGR+4.5%
3y CAGR+53.7%
5y CAGRBook Value
$332.748m
$2.054b
Assets$1.721b
Liabilities$1.509b
DebtDebt to Assets
73.5%
3.3x
Debt to EBITDAFree Cash Flow
$540.693m
+13.5%
1y CAGR+17.0%
3y CAGR+128.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company